Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

IBD

Measuring what counts—endoscopic assessment in IBD

Nature Reviews Gastroenterology & Hepatology volume 11, pages 9–10 (2014)Cite this article

Subjects

Endoscopic assessment in IBD provides direct visualization of the affected bowel mucosa. There is an important need for the meaningful measurement of these endoscopic images at the correct time point for medical decision-making and for clinical trials. European guidelines on endoscopy in IBD have recently been published.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Annese, V. et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J. Crohns Colitis http://dx.doi.org/10.1016/j.crohns.2013.09.016.

  2. Byers, T., Levin, B., Rothenberger, D., Dodd, G. D. & Smith, R. A. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J. Clin. 47, 154–160 (1997).

    Article  CAS  Google Scholar 

  3. Vienne, A. et al. Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. Aliment. Pharmacol. Ther. 34, 188–195 (2011).

    Article  CAS  Google Scholar 

  4. Daperno, M. et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest. Endosc. 60, 505–512 (2004).

    Article  Google Scholar 

  5. Bouguen, G. et al. Treat to target: a proposed new paradigm for the management of Crohn's disease. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2013.09.006.

  6. Gisbert, J. P. & Panes, J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 104, 760–767 (2009).

    Article  CAS  Google Scholar 

  7. Lahiff, C. et al. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 37, 786–794 (2013).

    Article  CAS  Google Scholar 

  8. Schreiber, S. et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357, 239–250 (2007).

    Article  CAS  Google Scholar 

  9. Hanauer, S. B. et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359, 1541–1549 (2002).

    Article  CAS  Google Scholar 

  10. Marshall, J. K. Reporting ileocolonoscopy in inflammatory bowel disease. Can. J. Gastroenterol. 20, 399–400 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Western University, 100 Perth Drive, London, N6A 5K8, ON, Canada

    Reena Khanna

  2. Division of Gastroenterology, University of California San Diego, 9500 Gliman Drive, La Jolla, 92093-0956, CA, USA

    Barrett G. Levesque & William J. Sandborn

Authors
  1. Reena Khanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barrett G. Levesque
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William J. Sandborn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William J. Sandborn.

Ethics declarations

Competing interests

R. Khanna declares no competing interests.

B. G. Levesque declares that he has acted as a Consultant for Prometheus Labs and Santarus.

W. J. Sandborn has received consulting fees from Abbott, ActoGeniX NV, AGI Therapeutics Inc, Alba Therapeutics Corp, Albireo, Alfa Wasserman, Amgen, AM-Pharma BV, Anaphore, Astellas, Athersys Inc, Atlantic Healthcare Ltd, Aptalis, BioBalance Corp, Boehringer- Ingelheim, Bristol-Myers Squibb, Celgene, Celek Pharmaceuticals, Cellerix SL, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado Biosciences, Cytokine Pharmasciences, Eagle Pharmaceuticals, EnGene Inc, Eli Lilly, Enteromedics, Exagen Diagnostics Inc, Ferring Pharmaceuticals, Flexion Therapeutics Inc, Funxional Therapeutics Ltd, Genzyme Corp, Gilead Sciences, Given Imaging, GlaxoSmithKline, Human Genome Sciences, Ironwood Pharmaceuticals, Janssen Pharmaceutical Research & Development, LLC; KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Lycera Corp, Medea Pharmaceuticals, Merck Research Laboratories, Merck Serono, Millenium Pharmaceuticals, Nisshin Kyorin Pharmaceuticals, Novo Nordisk, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics Inc, PDL Biopharma, Pfizer, Procter and Gamble, Prometheus Laboratories, ProtAb Ltd, Purgenesis Technologies Inc, Relypsa Inc, Roche, Salient Pharmaceuticals, Salix Pharmaceuticals, Santarus, Schering Plough, Shire Pharmaceuticals, Sigmoid Pharma Ltd, Sirtris Pharmaceuticals, SLA Pharma UK Ltd, Targacept, Teva Pharmaceuticals, Therakos, Tilliotts Pharma AG, TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics Ltd, Warner Chilcott UK Ltd and Wyeth; research grants from Abbott, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen Pharmaceutical Research & Development, LLC, Milennium Pharmaceuticals, Novartis, Pfizer, Procter and Gamble, Shire Pharmaceuticals and UCB Pharma; payments for lectures/speakers bureau from Abbott, Bristol-Myers Squibb and Janssen Pharmaceutical Research & Development, LLC; and holds stock/stock options in Enteromedics.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khanna, R., Levesque, B. & Sandborn, W. Measuring what counts—endoscopic assessment in IBD. Nat Rev Gastroenterol Hepatol 11, 9–10 (2014). https://doi.org/10.1038/nrgastro.2013.233

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2013.233

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing